News from delmar pharmaceuticals A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 01, 2015, 14:29 ET

DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and...

Jun 01, 2015, 08:35 ET

DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 29, 2015, 07:35 ET

DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 27, 2015, 07:05 ET

DelMar Pharmaceuticals Announces Upcoming Investor and Scientific Conference Presentations

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on...

May 18, 2015, 08:05 ET

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2015 Financial Results and Provides Corporate Update

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

May 07, 2015, 08:05 ET

DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing...

Apr 30, 2015, 07:05 ET

DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it will be presenting new data related to the...

Apr 20, 2015, 13:00 ET

DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 20, 2015, 08:00 ET

DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 19, 2015, 13:00 ET

DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven...

Apr 16, 2015, 08:05 ET

DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 07, 2015, 08:00 ET

DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Apr 01, 2015, 08:05 ET

DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has appointed biopharmaceutical industry veteran,...

Mar 03, 2015, 08:00 ET

DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing...

Mar 02, 2015, 11:17 ET

DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer...

Feb 24, 2015, 08:00 ET

DelMar Pharmaceuticals to Present Clinical and Preclinical Abstracts for VAL-083 at the American Association of Cancer Research (AACR) Annual Meeting in April 2015

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it will be presenting three abstracts based on...

Feb 12, 2015, 08:00 ET

DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company") today announced the filing of its financial statements for the six...

Feb 11, 2015, 08:13 ET

DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has appointed Lynda Cranston, BScN, MScN,...

Feb 10, 2015, 09:35 ET

DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants

 DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), today announced that it has completed...

Jan 13, 2015, 08:00 ET

DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company") today announced that the U.S. Patent and Trademark Office (USPTO) has issued a...